

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Parkinson's disease (PD)	Dopamine D2 receptor; dopamine D3 receptor	<p>Studies in rats identified a hybrid molecule with D2/D3 receptor agonist and iron chelation activities that could help treat PD. Excessive iron levels can trigger cell death. In a rat model of PD, the hybrid compound, as compared with Requip ropinirole, rescued motor dysfunction commonly associated with PD. Next steps could include studying the neuroprotective properties of the compound.</p> <p>GlaxoSmithKline plc markets the D2/D3 agonist Requip ropinirole to treat PD.</p> <p>SciBX 3(8); doi:10.1038/scibx.2010.252 Published online Feb. 25, 2010</p>	Patent pending; available for licensing	<p>Ghosh, B. <i>et al. J. Med. Chem.</i>; published online Feb. 16, 2010; doi:10.1021/jm901618d</p> <p>Contact: Alope K. Dutta, Wayne State University, Detroit, Mich. e-mail: adutta@wayne.edu</p>